Results for DNA & Clones ( 1201 )
- From: DKK27,225.00
DNA was prepared from cell line WM3301. WM3301 is a human metastatic melanoma cell line that displays flat cell morphology and requires insulin and 10% culture medium for growth. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including homozygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM3301 cells produce xenograft tumors when injected into immunocompromised mice.
- From: DKK54,630.00
DNA was prepared from cell line WM3301. WM3301 is a human metastatic melanoma cell line that displays flat cell morphology and requires insulin and 10% culture medium for growth. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including homozygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM3301 cells produce xenograft tumors when injected into immunocompromised mice.
- From: DKK16,313.00
DNA was prepared from cell line WM3311. These cells are known to have mutations in GRIN2A, PRDM1, TERT, and are upregulated in Notch2. These cells are different from many melanoma cell lines in that they lack the common V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This cell line is wild type for BRAF, N-RAS, c-KIT, and CDK4. WM3311 cells produce xenograft tumors when injected into immunocompromised mice.
- From: DKK27,225.00
DNA was prepared from cell line WM3311. These cells are known to have mutations in GRIN2A, PRDM1, TERT, and are upregulated in Notch2. These cells are different from many melanoma cell lines in that they lack the common V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This cell line is wild type for BRAF, N-RAS, c-KIT, and CDK4. WM3311 cells produce xenograft tumors when injected into immunocompromised mice.
- From: DKK54,630.00
DNA was prepared from cell line WM3311. These cells are known to have mutations in GRIN2A, PRDM1, TERT, and are upregulated in Notch2. These cells are different from many melanoma cell lines in that they lack the common V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This cell line is wild type for BRAF, N-RAS, c-KIT, and CDK4. WM3311 cells produce xenograft tumors when injected into immunocompromised mice.
- From: DKK16,313.00
DNA was prepared from cell line WM3406. WM3406 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. This cell line also expresses mutated PTEN gene and is wild type for BRAF, c-KIT and CDK4. WM3406 cells produce xenograft tumors when injected into immunocompromised mice.
- From: DKK27,225.00
DNA was prepared from cell line WM3406. WM3406 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. This cell line also expresses mutated PTEN gene and is wild type for BRAF, c-KIT and CDK4. WM3406 cells produce xenograft tumors when injected into immunocompromised mice.
- From: DKK54,630.00
DNA was prepared from cell line WM3406. WM3406 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. This cell line also expresses mutated PTEN gene and is wild type for BRAF, c-KIT and CDK4. WM3406 cells produce xenograft tumors when injected into immunocompromised mice.